The potential role of HER-2 in inducing resistance in CRC cells exposed to EGFR-inhibitors, was further investigated in a preclinical study where the impact of somatic mutations by introducing the HER2 V842I mutation, the most prevalent HER-2 mutation identified in CRC samples according to the Cancer Genome Atlas [80], into the cetuximab-sensitive colorectal cell line DiFi was assessed. The gene discussed is EGFR; the disease is colorectal carcinoma.